For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 22,010 | 22,547 | ||
| General and administrative | 5,391 | 5,231 | ||
| Total operating expenses | 27,401 | 27,778 | ||
| Loss from operations | -27,401 | -27,778 | ||
| Interest income | 2,254 | 1,828 | ||
| Change in fair value of convertible notes payable | 0 | 6,184 | ||
| Other expense | -28 | - | ||
| Total other expense, net | 2,226 | -4,356 | ||
| Net loss | -25,175 | -32,134 | ||
| Currency translation adjustment | 18 | -24 | ||
| Unrealized holding gain on investments | 35 | - | ||
| Comprehensive loss | -25,122 | -32,158 | ||
| Basic EPS | -0.48 | -0.86 | ||
| Diluted EPS | -0.48 | -0.86 | ||
| Basic Average Shares | 39,584,489 | 28,431,158 | ||
| Diluted Average Shares | 39,584,489 | 28,431,158 | ||
Jade Biosciences, Inc. (JBIO)
Jade Biosciences, Inc. (JBIO)